<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">760</article-id><article-id pub-id-type="doi">10.54101/ACEN.2021.3.5</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Analysing the reasons for rejection of neurosurgery intervention in patients with Parkinson’s disease referred to an extrapyramidal movement disorders clinic</article-title><trans-title-group xml:lang="ru"><trans-title>Анализ причин отказа в нейрохирургическом лечении пациентам с болезнью Паркинсона при направлении в экстрапирамидный центр</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6524-4490</contrib-id><name-alternatives><name xml:lang="en"><surname>Bril’</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Бриль</surname><given-names>Екатерина Витальевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Assoc. Prof., Department of neurology; Head</p></bio><bio xml:lang="ru"><p>к.м.н., доц. каф. неврологии, рук.</p></bio><email>e.brill@inbox.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2120-0146</contrib-id><name-alternatives><name xml:lang="en"><surname>Tomskiy</surname><given-names>Аleksey A.</given-names></name><name xml:lang="ru"><surname>Томский</surname><given-names>Алексей Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Head, Group of functional neurosurgery</p></bio><bio xml:lang="ru"><p>к.м.н., рук. группы функциональной нейрохирургии </p></bio><email>e.brill@inbox.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5776-3442</contrib-id><name-alternatives><name xml:lang="en"><surname>Poddubskaya</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Поддубская</surname><given-names>Анна Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>neuropsychologist, neurologist, Group of functional neurosurgery</p></bio><bio xml:lang="ru"><p>нейропсихолог группы функциональной нейрохирургии</p></bio><email>e.brill@inbox.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6412-8148</contrib-id><name-alternatives><name xml:lang="en"><surname>Gamaleya</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Гамалея</surname><given-names>Анна Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>neurologist, Group of functional neurosurgery</p></bio><bio xml:lang="ru"><p>врач-невролог группы функциональной нейрохирургии</p></bio><email>e.brill@inbox.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2168-2138</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedorova</surname><given-names>Natalya V.</given-names></name><name xml:lang="ru"><surname>Федорова</surname><given-names>Наталья Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof., Department of neurology</p></bio><bio xml:lang="ru"><p>д.м.н., проф. каф. неврологии</p></bio><email>e.brill@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Continuing Postgraduate Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного последипломного образования»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.N. Burdenko National Medical Research Center of Neurosurgery</institution></aff><aff><institution xml:lang="ru">ФГАУ «НМИЦ нейрохирургии имени академика Н.Н. Бурденко»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-10-04" publication-format="electronic"><day>04</day><month>10</month><year>2021</year></pub-date><volume>15</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>43</fpage><lpage>53</lpage><history><date date-type="received" iso-8601-date="2021-10-03"><day>03</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-03"><day>03</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Bril’ E.V., Tomskiy А.A., Poddubskaya A.A., Gamaleya A.A., Fedorova N.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Бриль Е.В., Томский А.А., Поддубская А.А., Гамалея А.А., Федорова Н.В.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Bril’ E.V., Tomskiy А.A., Poddubskaya A.A., Gamaleya A.A., Fedorova N.V.</copyright-holder><copyright-holder xml:lang="ru">Бриль Е.В., Томский А.А., Поддубская А.А., Гамалея А.А., Федорова Н.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/760">https://annaly-nevrologii.com/pathID/article/view/760</self-uri><abstract xml:lang="en"><p>We present findings of a 10-year retrospective study, analysing the reasons for rejection of neurosurgical intervention (deep brain stimulation or DBS) in patients with Parkinson’s disease, who were referred to an extrapyramidal movement disorders clinic and then to a neurosurgery centre. It was found that after screening, 78.6% of patients referred as candidates for neurosurgical treatment to an extrapyramidal movement disorders clinic were rejected, while 21.4% of patients were referred to a neurosurgery centre, where 12% underwent surgery. The main reasons for rejecting potential DBS candidates were: “early referral”, “inadequate pharmacotherapy”, “levodopa-resistant symptoms”, “atypical/secondary Parkinsonism”, “cognitive reasons”, “psychological reasons”, “comorbidity”, “abnormal MRI”, “poor response to levodopa medication” and “declined surgery”. Furthermore, the number of self-referrals decreased, the number of patients referred by neurologists increased, the number of rejections of ‘unsuitable’ DBS candidates decreased, and the number of ‘suitable’ candidates referred to the extrapyramidal centre increased during the time period of 10 years. In addition, the number of patients who were referred to the neurosurgery centre and underwent surgery there increased, which suggests greater awareness of the selection criteria among doctors, as well increased knowledge and experience among neurologists in both primary healthcare and specialized centres.</p></abstract><trans-abstract xml:lang="ru"><p>Представлены данные ретроспективного исследования с анализом причин отказа в нейрохирургическом лечении (стимуляции глубоких структур головного мозга — DBS) пациентам с болезнью Паркинсона при направлении в экстрапирамидный центр и далее в центр нейрохирургии на протяжении 10 лет. После проведения скрининга 78,6% пациентам, направленным как кандидаты на нейрохирургическое лечение в экстрапирамидный центр, было отказано в DBS, 21,4% больных были направлены в центр нейрохирургии, где 12% была проведена операция. Основные причины отказа при отборе пациентов на DBS: «раннее направление», «неадекватная медикаментозная терапия», «леводопа-нечувствительные симптомы», «атипичный/вторичный паркинсонизм», «когнитивные причины», «психические причины», «коморбидность», «аномальная МРТ», «низкая реакция на препараты леводопы» и «воздержавшиеся от операции». Также за 10 лет уменьшилось количество самостоятельных обращений, большее число пациентов стали направляться неврологами, уменьшилось количество отказов в DBS при направлении «неподходящих» кандидатов на операцию и увеличилось количество «подходящих» кандидатов, направленных в экстрапирамидный центр. Кроме того, возросло количество направленных и прооперированных больных в центре нейрохирургии, что позволяет предположить большую информированность врачей о критериях отбора, более высокий уровень знаний и опыта неврологов на уровне как первичного звена, так и специализированного центра.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Parkinson’s disease</kwd><kwd>deep brain stimulation</kwd><kwd>neurostimulation</kwd><kwd>electrode implantation in the brain</kwd><kwd>reasons for refusal to perform surgery</kwd><kwd>exclusion criteria</kwd><kwd>extrapyramidal movement disorders clinic</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>болезнь Паркинсона</kwd><kwd>deep brain stimulation</kwd><kwd>нейростимуляция</kwd><kwd>имплантация электродов в головной мозг</kwd><kwd>причины отказа в операции</kwd><kwd>критерии исключения</kwd><kwd>экстрапирамидный центр</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Okun M.S., Tagliati M., Pourfar M. et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol. 2005;62(8):1250–1255. DOI: 10.1001/archneur.62.8.noc40425. PMID: 15956104.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Okun M.S., Fernandez H.H., Pedraza O. et al. Development and initial vali-dation of a screening tool for Parkinson disease surgical candidates. Neurology. 2004;63(1):161–163. DOI: 10.1212/01.wnl.0000133122.14824.25. PMID: 15249630.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Morgante L., Morgante F., Moro E. et al. How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord. 2007;13:528–531. DOI: 10.1016/j.parkreldis.2006.12.013. PMID: 17347021</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Pal G.D., Persinger V., Bernard B. et al. The Core Assessment Program for Surgical Interventional Therapies in Parkinson’s Disease (CAPSIT-PD): tolerability of preoperative neuropsychological testing for deep brain stimulation in Parkinson’s disease. Mov Disord Clin Pract. 2015;2(4):379–383. DOI: 10.1002/mdc3.12213. PMID: 30363547.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Defer G.L., Widner H., Marié R.M. et al. Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord. 1999;14:572–584. DOI: 10.1002/1531-8257(199907)14:4&lt;572::aid-mds1005&gt;3.0.co;2-c. PMID: 10435493.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Okun M.S., Rodriguez R.L., Mikos A. et al. Deep brain stimulation and the role of the neuropsychologist. Clin Neuropsychol. 2007;21:162–189. DOI: 10.1080/13825580601025940. PMID: 17366283.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Moro E., Allert N., Eleopra R. et al. A decision tool to support appropriate referral for deep brain stimulation in Parkinson’s disease. J Neurol. 2009;256(1):83–88. DOI: 10.1007/s00415-009-0069-1. PMID: 19221846.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Willis A.W., Schootman M., Kung N. et al. Disparities in deep brain stimu-lation surgery among insured elders with Parkinson disease. Neurology. 2014; 82(2):163–171. DOI: 10.1212/WNL.0000000000000974. PMID: 25349276.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hassan A., Wu S.S., Schmidt P. et al. What are the issues facing Parkinson’s disease patients at ten years of disease and beyond? Data from the NPF-QII study. Parkinsonism Relat Disord. 2012;18(Suppl 3):S10–S14. DOI: 10.1016/j.parkreldis.2012.06.014. PMID: 22776044.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Lhommée E., Wojtecki L., Czernecki V. et al. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol. 2018;17(3):223–231. DOI: 10.1016/S1474-4422(18)30035-8. PMID: 29452685.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hesham A., Mehanna R., Machado A. et al. Comprehensive, multidisciplinary deep brain stimulation screening for Parkinson patients: no room for “short cuts”. Mov Disord Clin Pract. 2014;1(4):336–341. DOI: 10.1002/mdc3.12090. PMID: 30363983.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Schuepbach W.M., Rau J., Knudsen K. et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368(7):610–622. DOI: 10.1056/NEJMoa1205158. PMID: 23406026.</mixed-citation></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Tomskiy A.A., Bril’ E.V., Gamaleya A.A. Functional neurosurgery in Parkinson’s disease in Russia. Annals of clinical and experimental neurology. 2019;13(4):10–15. DOI: 10.25692/ACEN.2019.4.2. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Томский А.А., Бриль Е.В., Гамалея А.А. и др. Функциональная нейрохирургия при болезни Паркинсона в России. Анналы клинической и экспериментальной неврологии. 2019;13(4):10–15. DOI: 10.25692/ACEN.2019.4.2.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><mixed-citation>Dafsari H.S., Reker P., Stalinski L. et al. Quality of life outcome after subthalamic stimulation in Parkinson’s disease depends on age. Mov Disord. 2018;33(1):99–107. DOI: 10.1002/mds.27222. PMID: 29150860.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Romann A.J., Dornelles S., Maineri N.L. et al. Cognitive assessment instruments in Parkinson’s disease patients undergoing deep brain stimulation. Dement Neuropsychol. 2012;6(1):2–11. DOI: 10.1590/S1980-57642012DN06010002. PMID: 29213766.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Barbosa E.N.B.E., Charchat-Fichman H. Systematic review of neuropsychological instruments used in subthalamic nucleus deep brain stimulation in Parkinson’s disease patients. Dement Neuropsychol. 2019;13(2):162–171. DOI: 10.1590/1980-57642018dn13-020004. PMID: 31285790.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Fengler S., Kessler J., Timmermann L. et al. Screening for cognitive impairment in Parkinson’s disease: improving the diagnostic utility of the MoCA through subtest weighting. PloS One. 2016;11(7):e0159318. Doi: 10.1371/journal.pone.0159318. PMID: 27437705.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Nazem S., Siderowf A.D., Duda J.E. et al. Montreal cognitive assessment performance in patients with Parkinson’s disease with “normal” global cognition according to mini-mental state examination score. J Am Geriatr Soc. 2009;57(2):304–308. DOI: 10.1111/j.1532-5415.2008.02096.x. PMID: 19170786.</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Levin O.S. [Algorithms for the diagnosis and treatment of dementia]. Мoscow, 2014. 192 p. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Левин О.С. Алгоритмы диагностики и лечения деменции. М., 2014. 192 с.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><mixed-citation>Hoops S., Nazem S., Siderowf A.D. et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738–1745. DOI: 10. 1212/WNL.0b013e3181c34b47. PMID: 19933974.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Rothlind J.C., York M.K., Carlson K. et al. Neuropsychological changes following deep brain stimulation surgery for Parkinson’s disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy. J Neurol Neurosurg Psychiatry. 2015;86(6):622–629. DOI: 10.1136/jnnp-2014-308119. PMID: 25185211.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Rughani A., Schwalb J.M., Sidiropoulos C. et al. Congress of Neurological Surgeons systematic review and evidence-based guideline on subthalamic nucleus and globus pallidus internus deep brain stimulation for the treatment of patients with Parkinson’s disease: executive summary. Neurosurgery. 2018;82(6):753–756. DOI: 10.1093/neuros/nyy037. PMID: 29538685.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Smeding H.M., Speelman J.D., Koning-Haanstra M. et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology. 2006;66(12):1830–1836. DOI: 10.1212/01.wnl.0000234881.77830.66. PMID: 16801645.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Funkiewiez A., Ardouin C., Caputo E. et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(6):834–839. DOI: 10.1136/jnnp.2002.009803. PMID: 15145995.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Dubois B., Slachevsky A., Litvan I. et al. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55(11):1621–1626. DOI: 10.1212/wnl.55.11.1621. PMID: 11113214.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Chou K.L., Lenhart A., Koeppe R.A. et al. Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord. 2014;20(10):1076–1080. DOI: 10.1016/j.parkreldis.2014.07.008. PMID: 25085750.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Wyman-Chick K.A., Martin P.K., Barrett M.J. et al. Diagnostic accuracy and confidence in the clinical detection of cognitive impairment in early-stage Parkinson disease. J Geriatr Psychiatry Neurol, 2017;30(3):178–183. DOI: 10.1177/0891988717701001. PMID: 28351200.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Mondolo F., Jahanshahi M., Granà A. et al. The validity of the hospital anxi-ety and depression scale and the geriatric depression scale in Parkinson’s disease. Behav. Neurol. 2006;17(2):109–115. DOI: 10.1155/2006/136945. PMID: 16873922.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Leentjens A.F.G., Lousberg R., Verhey F.R.J. The psychometric properties of the hospital anxiety and depression scale in patients with Parkinson’s disease. Acta Neuropsychiatrica. 2001;13(4):83–85.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Accolla E.A., Pollo C. Mood effects after deep brain stimulation for Parkinson’s disease: an update. Front Neurol. 2019;10:617. DOI: 10.3389/fneur.2019.00617. PMID: 31258509.</mixed-citation></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Omarova S.M., Fedorova N.V., Tomskiy A.A. et al. Syndrome dopamine dysregulation and deep brain stimulation of the subthalamic nucleus in Parkinson’s disease. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2017;117(12):27–32. DOI: 10.17116/jnevro201711712127-32. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Омарова С.М., Федорова Н.В., Томский А.А. и др. Синдром дофаминовой дизрегуляции и хроническая стимуляции субталамического ядра при болезни Паркинсона. Журнал неврологии и психиатрии им. C.C. Корсакова. 2017;117(12):27–32. DOI: 10.17116/jnevro201711712127-32.</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><mixed-citation>Cummings J.L., Mega M., Gray K. et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. J Neurol. 1994;44(12):2308–2314. DOI: 10.1212/wnl.44.12.2308. PMID: 7991117.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Gilman S., Low P.A., Quinn N. et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94–98. DOI: 10.1016/s0022-510x(98)00304-9. PMID: 10223419.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Thavanesan N., Gillies M., Farrell M. et al. Deep brain stimulation in multiple system atrophy mimicking idiopathic Parkinson’s disease. Case Rep Neurol. 2014;6(3):232–237. DOI: 10.1159/000368571. PMID: 25473395.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Pitz V., Malek N., Tobias E.S. et al. The levodopa response varies in patho-logically confirmed Parkinson’s disease: a systematic review. Mov Disord Clin Pract. 2020;7(2):218–222. DOI: 10.1002/mdc3.12885. PMID: 32071945.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Machado A.G., Deogaonkar M., Cooper S. Deep brain stimulation for movement disorders: patient selection and technical options. Clevel Clin J Med. 2012;9(Suppl S2):S19–S24. DOI: 10.3949/ccjm.79.s2a.04. PMID: 22761265.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Saranza G., Lang A.E. Levodopa challenge test: Indications, protocol, and guide. J Neurol. 2020. DOI: 10.1007/s00415-020-09810-7. PMID: 32333167.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases.J Neurol Neurosurg Psychiatry. 1992;55(3):181–184. DOI: 10.1136/jnnp.55.3.181. PMID: 1564476.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Postuma R.B., Berg D., Stern M. et al. MDS clinical diagnostic criteria for Parkinson‘s disease. Mov Disord. 2015;30(12):1591–1601. DOI: 10.1002/mds.26424. PMID: 26474316.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Benabid A.L. Benazzouz A. Hoffmann D. et al. Long-term electrical inhibition of deep brain targets in movement disorders. Mov Disord. 1998,13(Suppl S3):119–125. DOI: 10.1002/mds.870131321. PMID: 9827607.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Merello M., Gerschcovich E.R., Ballesteros D., Cerquetti D. Correlation between the Movement Disorders Society Unified Parkinson’s Disease rating scale (MDS-UPDRS) and the Unified Parkinson’s Disease rating scale (UPDRS) during L-dopa acute challenge. Parkinsonism Relat Disord. 2011;17(9):705–707. DOI: 10.1016/j.parkreldis.2011.07.002. PMID: 21784692.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Kleiner-Fisman G., Herzog J., Fisman D.N. et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(Suppl 14):S290–S304. DOI: 10.1002/mds.20962. PMID: 16892449.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Morishita T., Rahman M., Foote K.D. et al. DBS candidates that fall short on a levodopa challenge test: alternative and important indications. Neurologist. 2011;17(5):263–268. DOI: 10.1097/NRL.0b013e31822d1069. PMID: 21881468.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Katz M., Kilbane C., Rosengard J. et al. Referring patients for deep brain stimulation: an improving practice. Arch Neurol. 2011;68(8):1027–1032. DOI: 10.1001/archneurol.2011.151. PMID: 21825238.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Lopiano L., Rizzone M., Bergamasco B. et al. Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion causes. J Neurol Sci. 2002;195(2):167–70. DOI: 10.1016/s0022-510x(02)00008-4. PMID: 11897249.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Ooi Y., Falowski S., Wang D. et al. Simultaneous use of neurostimulators in patients with a preexisting cardiovascular implantable electronic device. Neuromodulation. 2010;14(1):20–26. DOI: 10.1111/j.1525-1403.2010.00314.x. PMID: 21992157.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Capelle H., Simpson R.K.Jr., Kronenbuerger M. et al. Long-term deep brain stimulation in elderly patients with cardiac pacemakers. J Neurosurgery. 2005;102(1):53–59. DOI: 10.3171/jns.2005.102.1.0053. PMID: 15658096.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Ozben B., Bilge A., Yilmaz E., Adalet K. Implantation of a permanent pacemaker in a patient with severe Parkinson’s disease and a preexisting bilateral deep brain stimulator. Int Heart J. 2006;47(5):803–810. DOI: 10.1536/ihj.47.803. PMID: 17106151.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Ashino S., Watanabe I., Okumura Y. et al. Implantation of a pacemaker in a patient with severe Parkinson’s disease and a pre-existing bilateral deep brain stimulator. Europace. 2009;11(6):834–835. DOI: 10.1093/europace/eup117. PMID: 19447809.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Elliott M., Momin S., Fiddes B. et al. Pacemaker and defibrillator implantation and programming in patients with deep brain stimulation. Arrhythm Electrophysiol Rev. 2019;8(2):138–142. DOI: 10.15420/aer.2018.63.2. PMID: 31114689.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Dinkelbach L., Möller B., Witt K. et al. How to improve patient education on deep brain stimulation in Parkinson’s disease: the CARE Monitor study. BMC Neurol. 2017;17(1):36. DOI: 10.1186/s12883-017-0820-7. PMID: 28222691.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Mathers J., Rick C., Jenkinson C. et al. Patients’ experiences of deep brain stimulation for Parkinson’s disease: a qualitative systematic review and synthesis. BMJ Open. 2016;6(6):e011525. DOI: 10.1136/bmjopen-2016-011525. PMID: 27338883.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Wang T., Zhang Y., Pan Y. et al. Development and initial validation of the Chinese version of the Florida Surgical Questionnaire for Parkinson’s Disease. Parkinsons Dis. 2020;2020:8811435. DOI: 10.1155/2020/8811435. PMID: 33381295.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Wächter T., Mínguez-Castellanos A., Valldeoriola F. et al. A tool to improve pre-selection for deep brain stimulation in patients with Parkinson’s disease. J Neurol. 2011;258(4):641–646. DOI: 10.1007/s00415-010-5814-y. PMID: 21088849.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Khodakarami H., Farzanehfar P., Horne M. The use of data from the Parkinson’s KinetiGraph to identify potential candidates for device assisted therapies. Sensors (Basel). 2019;19(10):2241. DOI 10.3390/s19102241. PMID: 31096576.</mixed-citation></ref></ref-list></back></article>
